Hormonal and neurological decline during burnout or menopause creates significant healthcare costs and quality-of-life degradation. These innovations mitigate these symptoms through the precise standardization of ginsenoside and soybean-derived bioactive fractions.
Insufficient natural suppression of inflammatory pathways leads to tissue damage and metabolic dysfunction. Identifying potent bioactive compounds addresses the limitation of current therapies in managing systemic inflammation and obesity-related pathologies.